CompletedNCT00422214
Extended-release quetiapine for bipolar depression
About this title
Phase III/Seroquel SR Bipolar Depression Monotherapy - US
Read the official source — NCT00422214Medication studyAges 18–65United StatesBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 53 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateDecember 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 400
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00422214
- Official title
Show the full official title
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel SR®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham · Phoenix · Scottsdale
51 more locations
- Little Rock
- Cerritos
- La Mesa
- Los Angeles
- Newport Beach
- Northridge
- Oceanside
- Pico Rivera
- San Diego
- Wildomar
- Washington D.C.
- Bradenton
- Fort Lauderdale
- Jacksonville
- Leesburg
- Maitland
- North Miami
- Orlando
- Tampa
- West Palm Beach
- Smyrna
- Honolulu
- Joliet
- Greenwood
- Indianapolis
- Wichita
- Shreveport
- Rockville
- Farmington Hills
- St Louis
- Cherry Hill
- Clementon
- Brooklyn
- New York
- Staten Island
- Beachwood
- Cincinnati
- Dayton
- Oklahoma City
- Portland
- Salem
- Philadelphia
- Charleston
- Memphis
- Dallas
- Houston
- Charlottesville
- Virginia Beach
- Bellevue
- Seattle
- South Kirkland
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine fumarate (Seroquel) SR.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
